Please refer to important disclosures at the end of this report 1 Y/E Dec. (` cr) 2QCY2011 1QCY2011 % chg (qoq) 2QCY2010 % chg (yoy) Net sales 303 276 10 272 11.5 Other income 36.1 38 (5) 25 42.7 Operating profit 44 44 1 44 0.7 Net profit 50 51 (2) 42 17.2 Source: Company, Angel Research For 2QCY2011, Aventis Pharma (Aventis) reported in-line results at the top-line and net profit front, led by growth across the domestic market. Domestic sales grew by 12.1%, contributing around 80% to the total revenue; the remaining contribution came in from exports, which grew by 9.3% in 2QCY2s011. The company incurred planned expenditure in two of its critical projects ( Prayas, a project to deliver high-quality, low-cost healthcare to the rural population; and entry into the over-the-counter (OTC) market). These projects are slated to be the future growth drivers for the company. Given the valuations, we recommend a Reduce rating on the stock. Revenue growth led by the domestic segment: Aventis’ net sales grew by 11.5% yoy to `303cr ( `272cr) for the quarter, in-line with our estimates of `299cr, backed by 12.1% growth in the domestic segment. Export sales grew by 9.3% to `58.8cr. The company reported gross margin of 50.6% (49.6%), in-line with our estimates of 50.7%. OPM came in at 14.5% (16.0%), lower than our estimates of 16.0% for the quarter. Net profit came in at `49.7cr ( `53.0cr), up 17.2% yoy, lower than our estimates of `53cr. Outlook and valuation: We expect net sales to post a 13.6% CAGR to `1,401cr and EPS to register a 15.6% CAGR to `89.7cr over CY2010–12E. At current levels, the stock is trading at 24.6x and 23.5x CY2011E and CY2012E earnings, respectively. We recommend Reduc e on the stock with a target price of `1,937. Key financials Y E Dec. (`cr) CY2009 CY2010 CY2011E CY2012E Net sales 974 1,085 1,224 1,401 % chg (0.9) 11.3 12.8 14.4 Adj.net profit 157.4 155.0 197.0 206.4 % chg (5.3) (1.5) 27.1 4.8 EPS (`) 68.4 67.3 85.5 89.7 EBITDA (%) 15.2 13.2 14.9 15.3 P/E (x) 30.8 31.3 24.6 23.5 RoE (%) 17.9 15.9 18.3 17.1 RoCE (%) 14.8 12.6 14.8 15.7 P/BV (x) 5.2 4.8 4.2 3.8 EV/Sales (x) 4.4 3.9 3.4 2.9 EV/EBITDA (x) 28.8 29.3 22.9 19.0 Source: Company, Angel Research REDUCE CMP `2,091 Target Price `1,937Investment Period - Stock Info Sector Bloomberg Code Shareholding Pattern (%) Promoters 60.4 MF / Banks / Indian Fls 23.9 FII / NRIs / OCBs 9.9 Indian Public / Others 5.8 Abs. (%) 3m 1yr 3yr Sensex (4.9) 1.1 31.9 Aventis 4.9 10.1 173.4 10 18,197 5,482 AVPH.BO AVEN@IN 4,846 0.3 2380/1710 3023 Pharmaceutical Avg. Daily Volume Market Cap ( `cr) Beta 52 Week High / Low Face Value ( `) BSE Sensex NiftyReuters Code Sarabjit Kour Nangra +91 22 3935 7800 Ext: 6806 [email protected]Aventis Pharma Performance Highlights 2QCY2011 Result Update | Pharmaceutical July 29, 2011
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Research Team Tel: 022 - 3935 7800 E-mail: [email protected] Website: www.angelbroking.com
DISCLAIMER
This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investmentdecision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make
such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies
referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and
risks of such an investment.
Angel Broking Limited, its affiliates, directors, its proprietary trading and investment businesses may, from time to time, make
investment decisions that are inconsistent with or contradictory to the recommendations expressed herein. The views contained in this
document are those of the analyst, and the company may or may not subscribe to all the views expressed within.
Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and
trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's
fundamentals.
The information in this document has been printed on the basis of publicly available information, internal data and other reliablesources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as thisdocument is for general guidance only. Angel Broking Limited or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report .
Angel Broking Limited has not independently verified all the information contained within this document. Accordingly, we cannot testify,nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Angel Broking Limited endeavours to update on a reasonable basis the information discussed in this material, there may be regulatory,compliance, or other reasons that prevent us from doing so.
This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced,
redistributed or passed on, directly or indirectly.
Angel Broking Limited and its affiliates may seek to provide or have engaged in providing corporate finance, investment banking or
other advisory services in a merger or specific transaction to the companies referred to in this report, as on the date of this report or inthe past.
Neither Angel Broking Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in
connection with the use of this information.
Note: Please refer to the important `Stock Holding Disclosure' report on the Angel website (Research Section). Also, pleaserefer to the latest update on respective stocks for the disclosure status in respect of those stocks. Angel Broking Limited andits affiliates may have investment positions in the stocks recommended in this report.
Disclosure of Interest Statement Aventis Pharma
1. Analyst ownership of the stock No
2. Angel and its Group companies ownership of the stock No
3. Angel and its Group companies' Directors ownership of the stock No
4. Broking relationship with company covered No
Note: We have not considered any Exposure below ` 1 lakh for Angel, its Group companies and Directors.
Ratings (Returns): Buy (> 15%) Accumulate (5% to 15%) Neutral (-5 to 5%)Reduce (-5% to 15%) Sell (< -15%)